Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
Supply readiness follows months of manufacturing to ensure timely and ample supply
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Subscribe To Our Newsletter & Stay Updated